PV Bulletin

Technical Guidelines for Communication on Real-World Evidence Supporting the Extension of Pediatric Indications for Marketed Drugs (Draft for Comments)

The CDE is seeking public comments on a draft guideline regarding the use of real-world evidence (RWE) to support expanding drug indications for the pediatric population.

Primary source: Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

A draft guideline has been issued by the CDE outlining the framework for sponsors to use real-world evidence (RWE) when seeking to expand pediatric drug indications, highlighting the necessity for early discussions with the regulator on RWE study plans.

Why it matters

This change affects data collection and presentation for pediatric label extensions, potentially influencing the efficiency and speed of bringing pediatric drugs to market in China.

Action needed

Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Consultation
Policy status
consultation
Publication date
2026-07-14
Policy change
The CDE is seeking public comments on a draft guideline regarding the use of real-world evidence (RWE) to support expanding drug indications for the pediatric population. It establishes a framework for communication between sponsors and the CDE to improve the efficiency of pediatric research.

Key changes

Provides technical considerations for using RWE data sources, study design, and data analysis to support pediatric label extensions. Emphasizes the need for early communication with CDE on RWE study plans.

Affected workflows

Country Compliance

Responsible groups

Regulatory AffairsClinical DevelopmentPV Operations

PV impact

Affects how sponsors collect and present real-world safety and efficacy data for pediatric indication extensions in China.

View regulator source

Source document details

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 14, 2026

Full briefing

Practical implication

Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

The CDE draft guideline outlines a framework for using real-world evidence to support the extension of drug indications for pediatrics. It emphasizes the importance of early communication with the CDE and provides technical considerations for RWE data collection and analysis.

What changed: A draft guideline has been issued by the CDE outlining the framework for sponsors to use real-world evidence (RWE) when seeking to expand pediatric drug indications, highlighting the necessity for early discussions with the regulator on RWE study plans.

Why it matters: This change affects data collection and presentation for pediatric label extensions, potentially influencing the efficiency and speed of bringing pediatric drugs to market in China.

Practical implication: Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Consultation#Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA#labeling#policy-change#firecrawl-policy-agent

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward